Engineering immunomodulatory biomaterials for type 1 diabetes
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
A cure for type 1 diabetes (T1D) would help millions of people worldwide but remains elusive to date. Tolerogenic vaccines and β-cell replacement therapy are complementary therapies that seek to address aberrant T1D autoimmune attack and subsequent β-cell loss. However, both approaches require some form of systemic immunosuppression, imparting risks to the patient. Biomaterials-based tools enable localized and targeted immunomodulation, and biomaterial properties can be designed and combined with immunomodulatory agents to locally instruct specific immune responses. In this Review, we discuss immunomodulatory biomaterial platforms for the development of T1D tolerogenic vaccines and β-cell replacement devices. We investigate nanoparticles and microparticles for the delivery of tolerogenic agents and autoantigens and as artificial antigen-presenting cells, and we highlight how bulk biomaterials can be used to provide immune tolerance. We examine biomaterials for drug delivery and as immuno-isolation devices for cell therapy and islet transplantation and explore synergies with other fields for the development of new T1D treatment strategies.Type 1 diabetes is an autoimmune disease that causes the destruction of pancreatic β-cells, which results in an insulin deficiency. In this Review, the authors discuss immunomodulatory biomaterials for β-cell replacement and for the induction of tolerogenic immune responses to prevent, delay or reverse the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foreign body reaction to biomaterials
Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.004 · Cited by 5,138
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Cited by
Design Challenges in Polymeric Scaffolds for Tissue Engineering
Echeverria Molina, M. I., Malollari, K. G., & Komvopoulos, K. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.617141 · Cited by 397
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Keirouz, A., Chung, M., Kwon, J., Fortunato, G., & Radacsi, N. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1626 · Cited by 277
Wang, X., Wang, K., Yu, M., Velluto, D., Hong, X., Wang, B., Chiu, A., Melero-Martin, J. M., Tomei, A. A., & Ma, M. (2022) · Science Advances · doi:10.1126/sciadv.abn0071 · Cited by 62
Samojlik, M. M., & Stabler, C. L. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.039 · Cited by 38
Self-citation
Metadata
- Authors
- Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G.
- Venue
- Nature Reviews Materials
- Published
- 2019-05-17
- Volume
- 4
- Issue
- 6
- Pages
- 429-450
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W2945971202
- Cited by
- 125
- References
- 45
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineering immunomodulatory biomaterials for type 1 diabetes. https://app.cochat.ai/papers/10.1038/s41578-019-0112-5
- The paper
- Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G. (2019). Engineering immunomodulatory biomaterials for type 1 diabetes. Nature Reviews Materials. https://doi.org/10.1038/s41578-019-0112-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.